The medical therapy of reflux oesophagitis.
Besides changes in behaviour and lifestyle we nowadays have the choice of specific drugs in the treatment of reflux oesophagitis. A distinction can be made in motility modulating drugs, which stimulate oesophageal peristalsis and LOS pressure, mucosa-protecting drugs, which form a protective layer on the oesophageal mucosa, acid neutralizing (antacids) and acid suppressing drugs (H2-receptor antagonists, omeprazole). So far the results of medical therapy of reflux oesophagitis are still suboptimal. Giving the H2-receptor antagonists with the evening meal would possibly be more appropriate. A valid alternative is the mucosa-protecting agent sucralfate. Monotherapy will probably be insufficient for full healing, which explains why trials of combination therapy (H2-receptor antagonists plus sucralfate or plus cisapride) are being conducted. If omeprazole becomes available, it will revolutionize the therapy of severe reflux oesophagitis. Many questions (dose, duration, maintenance, safety monitoring etc.) remain to be determined.
D000863:Antacids / Q000627:therapeutic use; D018723:Bethanechol; D001626:Bethanechol Compounds / Q000627:therapeutic use; D002927:Cimetidine / Q000627:therapeutic use; D020117:Cisapride; D004294:Domperidone / Q000627:therapeutic use; D004942:Esophagitis, Peptic / Q000188:drug therapy*; D005764:Gastroesophageal Reflux / Q000517:prevention & control*; D006801:Humans; D008787:Metoclopramide / Q000627:therapeutic use; D009853:Omeprazole / Q000627:therapeutic use; D010880:Piperidines / Q000627:therapeutic use; D011899:Ranitidine / Q000627:therapeutic use; D013392:Sucralfate / Q000627:therapeutic use
D000863:Antacids; D001626:Bethanechol Compounds; D010880:Piperidines; D018723:Bethanechol; D013392:Sucralfate; D004294:Domperidone; D002927:Cimetidine; D011899:Ranitidine; D009853:Omeprazole; D008787:Metoclopramide; D020117:Cisapride